Form 4: Ligand Pharmaceuticals Director Stephen L. Sabba Reports Acquisition of Stock and Options

Director Stephen L. Sabba reports acquisition of Ligand Pharmaceuticals stock and options via grant.

Summary

• On June 14, 2024, Stephen L. Sabba, a director of Ligand Pharmaceuticals, acquired 1,252 shares of common stock in the form of restricted stock units (RSUs) and options to purchase 5,444 shares of common stock.
• The RSUs and options were granted by the Board of Directors at their annual meeting.
• The RSUs and options fully vest on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date.
• Following the transaction, Sabba directly owns 30,178 shares of Ligand Pharmaceuticals common stock and options to purchase 5,444 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating standard compensation practices. The director's acquisition of shares and options suggests a degree of confidence, but it's not overwhelmingly positive.

Positives

• The acquisition of stock and options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The RSUs and options vest on the earlier of the next annual meeting of the Company stockholders following the grant date or on the first anniversary of the date of grant.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Stakeholder Impact

• The acquisition of shares by a director can positively influence shareholder sentiment.

Key Dates